Colorectal peritoneal metastases treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Should we consider the primary tumour site?

Fiche publication

Date publication

avril 2026

Journal

Surgical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric

Tous les auteurs :
Tidadini F, Glehen O, Sourrouille I, Dumont F, Quesada JL, Eveno C, Marchal F, Amroun KL, Abba J, Pocard M, Kepenekian V, Fernandez de Sevilla E, Louis-Gaubert C, Foote A, Sage PY, Malgras B, Trilling B, Faucheron JL, Ezanno AC, Arvieux C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42061941

Résumé

Several publications have shown that cancers of the colon and of the rectum are significantly different, and tumor location is a major prognostic factor for survival. However, colorectal peritoneal metastases (CRPM) is still considered as a homogeneous and a single disease without differentiating between colonic or rectal origin. We asked whether the primary tumor location influences the survival and surgical outcomes of patients with colonic (C_PM) and rectal peritoneal metastases (R_PM) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).